Table 4 Cytokine polymorphisms in patients with rheumatoid arthritis and controls in Syria and France.
| A | ||||||
|---|---|---|---|---|---|---|
| Syria | France | |||||
| Patients (n = 156) | Controls (n = 120) | Odds ratio (95% CI) | Patients (n = 512) | Controls (n = 471) | Odds ratio (95% CI) | |
| IL‐1B +3954 | ||||||
| C/C | 88 | 64 | 1 | 300 | 281 | 1 |
| (56.4%) | (53.3%) | (58.6%) | (59.7%) | |||
| C/T or T/T | 68 | 56 | 0.88 | 212 | 190 | 1.04 |
| (43.6%) | (46.7%) | (0.6 to 1.4) | (41.4%) | (40.3%) | 0.8 to 1.3) | |
| IL‐1‐RN +2018 | ||||||
| T/T | 81 | 70 | 1 | 292 | 251 | 1 |
| (51.9%) | (58.3%) | (57.1%) | (53.3%) | |||
| T/C or C/C | 75 | 50 | 1.3 | 220 | 220 | 0.9 |
| (48.1%) | (41.7%) | (0.8 to 2.1) | (42.9%) | (46.7%) | (0.7 to 1.1) | |
| TNFα −238 | ||||||
| G/G | 138 | 109 | 1 | 479 | 416 | 1 |
| (88.5%) | (90.8%) | (93.5%) | (88.3%) | |||
| G/A or A/A | 18 | 11 | 1.29 | 33 | 55 | 0.5† |
| (11.5%) | (9.2%) | (0.6 to 2.8) | (6.5%) | (11.7%) | (0.3 to 0.8) | |
| TNFα –308 | ||||||
| G/G | 147 | 110 | 1 | 376 | 346 | 1 |
| (94.2%) | (91.7%) | (73.5%) | (73.6%) | |||
| G/A or A/A | 9 | 10 | 0.67 | 136 | 125 | 1.0 |
| (5.8%) | (8.3%) | (0.3 to 1.7) | (26.5%) | (26.4%) | (0.8 1.3) | |
| B | ||||||||
|---|---|---|---|---|---|---|---|---|
| Syrian patients (n = 156) | French patients (n = 512) | |||||||
| With destruction (n = 156) | Without destruction (n = 120) | Odds ratio (95% CI) | χ2 | With destruction (n = 156) | Without destruction (n = 120) | Odds ratio (95% CI) | χ2 | |
| IL‐1B +3954 | ||||||||
| C/C | 62 | 26 | 1 | 137 | 146 | 1 | ||
| (39.7%) | (16.7%) | (28.9%) | (30.8%) | |||||
| C/T or T/T | 47 | 21 | 0.9 | 0.03 | 99 | 92 | 1.15 | 0.53 |
| (30.1%) | (13.5%) | (0.5 to 1.9) | (20.9%) | (19.4%) | (0.8 to 1.7) | |||
| IL‐1‐RN +2018 | ||||||||
| T/T | 25 | 22 | 1 | 133 | 135 | 1 | ||
| (16.0%) | (14.1%) | (28.1%) | (28.5%) | |||||
| T/C or C/C | 50 | 59 | 0.7 | 0.7 | 103 | 103 | 1.02 | 0.01 |
| (32.1%) | (37.8%) | (0.4 to 1.5) | (21.7%) | (21.7%) | (0.7 to 1.5) | |||
| TNFα −238 | ||||||||
| G/G | 92 | 45 | 1 | 218 | 225 | 1 | ||
| (59.0%) | (28.8%) | (46.0%) | (47.5%) | |||||
| G/A or A/A | 17 | 2 | 4.16 | 3.9* | 18 | 13 | 1.4 | 0.9 |
| (10.9%) | (1.3%) | (1.02 to 16.9) | (3.8%) | (2.7%) | (0.7 to 3.0) | |||
| TNFα −308 | ||||||||
| G/G | 103 | 44 | 1 | 177 | 171 | 1 | ||
| (66.1%) | (28.2%) | (37.3%) | (36.1%) | |||||
| G/A or A/A | 6 | 3 | 0.85 | 0.05 | 59 | 67 | 0.8 | 0.6 |
| (3.8%) | (1.9%) | (0.2 to 3.6) | (12.4%) | (14.1%) | (0.6 to 1.3) | |||
TNF, tumour necrosis factor.
*In unvariate analysis, TNFα −238 single‐nucleotide polymorphism was associated with rheumatoid arthritis susceptibility in Syria but not in France. However, this SNP was associated with rheumatoid arthritis severity in France, but not in Syria.